Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Tongue Neoplasms 1Sturge-Weber Syndrome 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Port-Wine Stain 1Peutz-Jeghers Syndrome 1Neuroendocrine Tumors 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glaucoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sturge-Weber Syndrome × Everolimus × Clear all
NCT01997255 2016-05-05

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Baylor College of Medicine

Phase 2 Withdrawn

Epilepsy, Glaucoma, Sturge-Weber Syndrome, Port-Wine Stain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡